Immunoglobulin G1 [101-Glycine,234-Phenylalanine,235-Glutamic Acid,265-Alanine,405-Leucine,De-C-Terminal-Lysine], Anti-(Human Cd3 Antigen) (Human-Mus Musculus Monoclonal Igg1-Hucacao-H101G-Feal ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Igg1-Hucacao-H101G-Feal ?-Chain, (234?226?),(237?229?)-Bis(Disulfide) With Immunoglobulin G1 [234-Phenylalanine,235-Glutamic Acid,265-Alanine,409-Arginine] Anti-(Human B7 Homolog 4 Protein) (Human Monoclonal Igg1-7724-084-N52S-Fear ?1-Chain) Disulfide With Human Monoclonal Igg1-7724-084-N52S-Fear ?-Chain
Endometrial Cancer
Explore 44 assets in Endometrial Cancer →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Genmab
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05180474CT.gov GEN1047 for Solid Tumors - First in Human (FIH) Trial | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometrial Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1 [101-Glycine,234-Phenylalanine,235-Glutamic Acid,265-Alanine,405-Leucine,De-C-Terminal-Lysine], Anti-(Human Cd3 Antigen) (Human-Mus Musculus Monoclonal Igg1-Hucacao-H101G-Feal ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Igg1-Hucacao-H101G-Feal ?-Chain, (234?226?),(237?229?)-Bis(Disulfide) With Immunoglobulin G1 [234-Phenylalanine,235-Glutamic Acid,265-Alanine,409-Arginine] Anti-(Human B7 Homolog 4 Protein) (Human Monoclonal Igg1-7724-084-N52S-Fear ?1-Chain) Disulfide With Human Monoclonal Igg1-7724-084-N52S-Fear ?-Chain (this asset) | Genmab | P1/2 | CCC · 48 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BBB |
| Lenvatinib | Merck Sharp & Dohme LLC | P3 | BB |
| Pembrolizumab | Eli Lilly and Company | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Eli Lilly and Company | P3 | BB |
| Carboplatin | Eli Lilly and Company | P3 | BB |
| Adriamycin | Yonsei University | P3 | BB |
| Technetium-99 | Institut de Cancérologie de Lorraine | P3 | BB |
| Indocyanine Green | Institut de Cancérologie de Lorraine | P3 | BB |
+42 more in the Endometrial Cancer cohort
Other indications for Immunoglobulin G1 [101-Glycine,234-Phenylalanine,235-Glutamic Acid,265-Alanine,405-Leucine,De-C-Terminal-Lysine], Anti-(Human Cd3 Antigen) (Human-Mus Musculus Monoclonal Igg1-Hucacao-H101G-Feal ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Igg1-Hucacao-H101G-Feal ?-Chain, (234?226?),(237?229?)-Bis(Disulfide) With Immunoglobulin G1 [234-Phenylalanine,235-Glutamic Acid,265-Alanine,409-Arginine] Anti-(Human B7 Homolog 4 Protein) (Human Monoclonal Igg1-7724-084-N52S-Fear ?1-Chain) Disulfide With Human Monoclonal Igg1-7724-084-N52S-Fear ?-Chain
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P1/2 | CCC · 48 |
| Ovarian Cancer | — | P1/2 | CCC · 48 |
| Non-Small Cell Squamous Lung Carcinoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1 [101-Glycine,234-Phenylalanine,235-Glutamic Acid,265-Alanine,405-Leucine,De-C-Terminal-Lysine], Anti-(Human Cd3 Antigen) (Human-Mus Musculus Monoclonal Igg1-Hucacao-H101G-Feal ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Igg1-Hucacao-H101G-Feal ?-Chain, (234?226?),(237?229?)-Bis(Disulfide) With Immunoglobulin G1 [234-Phenylalanine,235-Glutamic Acid,265-Alanine,409-Arginine] Anti-(Human B7 Homolog 4 Protein) (Human Monoclonal Igg1-7724-084-N52S-Fear ?1-Chain) Disulfide With Human Monoclonal Igg1-7724-084-N52S-Fear ?-Chain in Endometrial Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-101-glycine234-phenylalanine235-glutamic-acid265-alanine405-leucinede-c-terminal-lysine-anti-human-cd3-antigen-human-mus-musculus-monoclonal-igg1-hucacao-h101g-feal-1-chain-disulfide-with-human-mus-musculus-monoclonal-igg1-hucacao-h101g-feal-chain-234226237229-bisdisulfide-with-immunoglobulin-g1-234-phenylalanine235-glutamic-acid265-alanine409-arginine-anti-human-b7-homolog-4-protein-human-monoclonal-igg1-7724-084-n52s-fear-1-chain-disulfide-with-human-monoclonal-igg1-7724-084-n52s-fear-chain-endometrial-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →